According to WHO, life expectancy in most industrialized nations currently exceeds 80 years due to early disease detection, the availability of modern healthcare facilities, and increased healthcare spending. According to the Surveillance Epidemiology and End Results (SEER) Database of the National Cancer Institute, 38% of women and 43% of men are expected to acquire cancer over their lifetime. Nearly two-thirds of all new cancer cases are detected in adults 65 and older, indicating that ageing can make people more sensitive to cancer. Blood screening can help with early diagnosis and has a huge impact on the management of cancer, infectious disorders, and cardiovascular diseases.
Access Full Report : https://databridgemarketresearch.com/reports/global-blood-screening-market
Data Bridge Market Research analyses that the Blood Screening Market was valued at USD 2.5 billion in 2021 and is expected to reach USD 3.91 billion by 2029, registering a CAGR of 5.75% during the forecast period of 2022 to 2029. The increased incidences of novel infections and the growing elderly population are the major factors driving the growth of the blood screening market. Furthermore, rising levels of investment in the development of new technology, as well as favorable government policies regarding blood screening, contribute to the market's overall growth.
Growing number of blood donation activities is expected to drive the market's growth rate
Rising blood donations, an increase in the incidence of infectious diseases, and government measures are driving the market's rapid growth. According to a December 2021 article headlined 'Operative Risk,' roughly 234 million major procedures are conducted worldwide each year. Blood transfusions are widely used in complex childbirths to prepare for childhood acute anemia, trauma, and congenital maternal blood abnormalities. Furthermore, according to the World Health Organization (WHO) Factsheet for June 2020, 118.5 million blood donations are collected globally, with 40% of those collected in high-income countries, which account for 16% of the global population. Contributions of blood account for 31.5% of contributions in high-income countries, 15.9% in upper-middle-income countries, 6.8% in lower-middle-income countries, and 5.0% in low-income countries.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products and Services (Reagents and Kits, Instruments, Software and Services), Technology (Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blot Assay, Next-Generation Sequencing, Others), Disease Type (Respiratory Diseases, Diabetes Mellitus, Oncology, Cholesterol, HIV/AIDS, Cold and Flu, Infectious Diseases, Others), End User (Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Enzo Biochem Inc. (U.S.), meridianbioscience. (Singapore), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher. (U.S.), BioMérieux SA (France), Beckman Coulter, Inc. (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Cepheid (U.S.), GENERAL ELECTRIC (U.S.), Digirad Corporation. (U.S.), Neusoft Corporation (China), CANON MEDICAL SYSTEMS CORPORATION (Japan), GRIFOLS INTERNATIONAL, S.A. (Spain), Siemens (Germany), Ortho Clinical Diagnostics (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Blood screening market is segmented on the basis of products and services, technology, disease type and end user.
- On the basis of products and services segment, the blood screening market is segmented into reagents and kits, instruments and software and services.
The reagents and kits segment of product and services segment dominates the blood screening market
Reagents and kits dominate the market with a market share of over 60%. This is due to the high demand for reagents and kits from blood banks, hospitals, and clinical laboratories.
- On the basis of technology, the blood screening market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test (NAT) dominates the market with a market share of over 30%. This is due to the high sensitivity and specificity of NAT tests, which makes them ideal for detecting a wide range of infectious diseases.
- On the basis of disease type segment, the blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, Infectious Diseases and others. Respiratory diseases dominate the market with a market share of over 25%. This is due to the high prevalence of respiratory diseases such as pneumonia, influenza, and tuberculosis.
- The end user segment in the blood screening market is segmented into diagnostic centers, blood bank, hospitals, clinics and ambulatory surgical centers.
The diagnostic centers segment of end user segment dominates the blood screening market
Diagnostic centers dominate the market with a market share of over 40%. This is due to the increasing number of diagnostic centers and the growing demand for blood screening services.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Enzo Biochem Inc. (U.S.), meridianbioscience. (Singapore), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher. (U.S.), BioMérieux SA (France), Beckman Coulter, Inc. (U.S.), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Cepheid (U.S.), GENERAL ELECTRIC (U.S.), Digirad Corporation. (U.S.), Neusoft Corporation (China), CANON MEDICAL SYSTEMS CORPORATION (Japan), GRIFOLS INTERNATIONAL, S.A. (Spain), Siemens (Germany), Ortho Clinical Diagnostics (U.S.).
Market Development
- In 2022, Guardant Health, a leading precision oncology company, launched an investigational next-generation Guardant SHIELD multi-cancer assay. This assay is designed to analyze approximately 20,000 epigenomic biomarkers, which are molecules that can be used to identify changes in DNA. These changes can be indicative of early-stage cancer. The Guardant SHIELD assay can detect a wide range of solid tumors, including colorectal cancer, lung cancer, breast cancer, and pancreatic cancer. It can also detect early-stage cancers that are not yet visible on imaging tests.
- In 2022, Accelerate Diagnostics launched the Accelerate Arc system. This system is designed to quickly and accurately identify microbes in positive blood cultures. Blood cultures are tests that are used to grow bacteria or other microbes from blood samples. The Accelerate Arc system can identify microbes in as little as two hours, which can help doctors to start treatment for infections sooner.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the blood screening market during the forecast period 2022-2029
North America is currently the dominating region in the global blood screening market. North America has a high prevalence of infectious diseases such as HIV/AIDS, hepatitis B and C, and syphilis. This has led to a high demand for blood screening services in the region.
Asia-Pacific is estimated to be the fastest growing region in the blood screening market in the forecast period 2022-2029
Asia-Pacific is projected to grow at the highest CAGR over the next few years. There is a growing awareness about the importance of blood donation in Asia-Pacific. This has led to an increase in the number of blood donors in the region.
For more detailed information about the blood screening market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-blood-screening-market
